

Journal Pre-proof

Concerns regarding Glomerular Disease in Chronic Graft versus Host Disease (cGVHD)

Karishma Bai Priyanka Sara Khan



PII: S0211-6995(25)00137-7

DOI: <https://doi.org/doi:10.1016/j.nefro.2025.501427>

Reference: NEFRO 501427

To appear in: *NEFROLOGÍA*

Received Date: 1 September 2025

Please cite this article as: Bai K, Priyanka, Khan S, Concerns regarding Glomerular Disease in Chronic Graft versus Host Disease (cGVHD), *NEFROLOGÍA* (2025), doi: <https://doi.org/10.1016/j.nefro.2025.501427>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología.

Letter To the Editor

Title:

Concerns regarding Glomerular Disease in Chronic Graft versus Host Disease (cGVHD)

Karishma Bai^a, Priyanka^b, Sara Khan^c

^a People's University of Medical and Health Sciences for Women, Nawabshah – SBA, Sindh , Pakistan.

^adrkarishmaomparkash@gmail.com

^b People's University of Medical and Health Sciences for Women, Nawabshah – SBA, Sindh, Pakistan.

^bpriyankabansari75@gmail.com

^c Karachi Metropolitan University, Sindh ,Pakistan

^csarakhanakbar.sk@gmail.com

Dear Editor,

We read with great interest the article titled "Glomerular disease in chronic graft versus host disease " by Peluffo et al, which highlights a rare, but important complication of the chronic graft- versus-host disease (GVHD) - glomerular disease after allogeneic stem cell transplantation (ASCT)¹. The authors deserve a huge credit for addressing histopathological and clinical patterns of the renal involvement in cGVHD patients, however , we would like to present several points for consideration regarding it's methodology , interpretation and generalizability.

Seven patients biopsied during the study period were included. Four were male and three were female. We are writing this to express concern on small sample size included in study period. These types of studies are relatively straightforward and are well suited for publication, but they make difficult to detect true effects, so they are not as such reliable and reduce generalizability of findings to the broader population. In contrast larger sample sizes are more accurate and reduce false positive results².

The exclusion criteria are important in study design to ensure participants safety, to minimize confounding variables, maintain ethical standards, enhancing the validity of study. The absence of such criteria restricts the generalizability of findings and raises question on homogeneity of the study. I respectfully suggest that well justified exclusion criteria must be addressed in future study³.

The calcineurin inhibitor- Cyclosporine used frequently in this study as prophylaxis ofGVHD is itself a nephrotoxic drug⁴. Glomerular disease i.e. Thrombotic micro-Pathy is well known to be caused by calcineurin inhibitors (CNIs)⁵. The authors did not assess whether the nephrotoxic effects are truly caused by GVHD, or they are the side effects of the calcineurin inhibitors, and the authors also didn't report the serum levels and monitoring ofCyclosporine⁶ .This omission limits the causality between cGVHD and kidney diseases in this study. Therefore, I believe this point need further discussion in future research on glomerular disease after allogeneic stem cell transplantation (ASCT).

A limitation of this study lies in the wide and heterogeneous treatment regimens used for immunosuppression. While corticosteroids were administered to each patient, other drugs like rituximab, mycophenolate mofetil, cyclosporine, and everolimus were used differently in different cases. This heterogeneity in treatment limits the effectiveness of specific therapies. However, rituximab was effective in podocytopathy cases but as this study includes very small sample size, so it prevents any firm conclusions regarding its efficacy⁷.

The study reports follow-up across patients ranging from just 14 to 100 months (median values often around 24–34 months) While some patients were observed up to ~8 years (3240 days → ~108 months), this remains limited for glomerular diseases with potential for late relapse—e.g.,

membranous nephropathy often relapses years later—and for chronic GVHD sequelae. Membranous nephropathy and other glomerulopathies have well-documented patterns of late relapse (5–10+ years post remission).

With most patients only observed ≤ 8 years, the risk of relapse or progression to CKD/ESRD beyond the follow-up window remains unquantified. The study focuses primarily on remission rates (CR/PR), but does not report long-term outcomes like progression to CKD stages, sustained proteinuria, or GFR trends.

Without extended monitoring, it's impossible to assess chronic kidney disease progression—especially following initial remission. The heterogeneous follow-up durations—e.g., one patient followed for only 14 months vs. another for 100 months—introduce inconsistencies in outcome assessment and risk evaluation. Such variability complicates comparisons and pooling of data⁸.

Overall, this study provides valuable insights into the under recognized complication of GVHD. However, future studies would benefit from including comprehensive drug monitoring, treatment homogeneity, larger sample size, and a systematic evaluation of Calcineurin inhibitors toxicity to fully clarify underlying causes of glomerular diseases in these patients. We are looking forward to seeing further research on this topic.

Conflicts of Interest:

The authors declare no conflicts of interest.

REFERENCES:

1-Peluffo L, Barceló L, Otatti G, Urrestarazu A, Coitiño R, Baccino C, et al. Glomerular disease in chronic graft versus host disease. *Nefrologia*. 2025 May;45(5):381–7. doi:10.1016/j.nefro.2024.09.002

2-Yap DYH, Lie D, Lau T, Tang A, Chan G, Chan TSY, et al. Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation. *Clin Kidney J*. 2022 Dec 10;16(6):976–84. doi:10.1093/ckj/sfac262

3-Zhao AT, Filip Pirs, Steinberg SM, Holtzman NG, Schulz E, Mina A, et al. Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease. *Bone Marrow Transplant*. 2023 Sep 8;58(12):1377–83. doi:10.1038/s41409-023-02094-2

4-Fellström B. Cyclosporine nephrotoxicity. *Transplant Proc*. 2004 Mar;36(2 Suppl):220S–3S. doi:10.1016/j.transproceed.2004.01.021.

5-Pham PT, Peng A, Wilkinson AH, Gritsch HA, Lassman C, Pham PC, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. *Am J Kidney Dis*. 2000;36(4):844–50. doi:10.1053/ajkd.2000.17690

6-Kennedy MS, Yee GC, McGuire TR, Leonard TM, Crowley JJ, Deeg HJ. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. *Transplantation*. 1985 Sep;40(3):249–53. doi:10.1097/00007890-198509000-00006

7-Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. *Bone Marrow Transplant*. 2007 Jun 4;40(3):273–7. doi:10.1038/sj.bmt.1705725

8-Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. *Blood*. 2015 Jan 22;125(4):606–15. doi:10.1182/blood-2014-09-551994